AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12697108 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 10231930 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) and serum prostate specific antigen (PSA) > 4.0 ng/ml
Number of subjects: 12542
Study 10231930 — intervention group
Group type: COMPARATOR
Intervention: Digital rectal examination (DRE) alone
Number of subjects: 12542
Study 8910238 — intervention group
Group type: EXPERIMENTAL
Intervention: P40 component presence
Number of subjects: 145
Study 1423942 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril 25 mg every 12 hours (group 1)
Number of subjects: 16
Study 1423942 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril 100 mg every 12 hours (group 2)
Number of subjects: 16
Study 1423942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3883066 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day surgery for tubal ligation
Number of subjects: 182
Study 3883066 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day surgery for hernia repair
Number of subjects: 182
Study 3883066 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day surgery for meniscectomy
Number of subjects: 182
Study 3883066 — intervention group
Group type: COMPARATOR
Intervention: Inpatient surgery
Number of subjects: 182
Study 3883066 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day surgery
Number of subjects: 182
Study 3883066 — intervention group
Group type: COMPARATOR
Intervention: One-day surgery and inpatient care
Number of subjects: 182
Study 30796651 — intervention group
Group type: EXPERIMENTAL
Intervention: MammaPrint® (MP)
Number of subjects: 452
Study 30796651 — intervention group
Group type: EXPERIMENTAL
Intervention: BluePrint®
Number of subjects: 452
Study 28887068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation services targeting physical impairments and immobility via the TCM‐RS
Number of subjects: 516
Study 28887068 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM‐RS plus conventional TCM pain management (TCM‐RS+Pain)
Number of subjects: 516
Study 28887068 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 516
Study 27054824 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-reported alliance in alliance-focused therapy
Number of subjects: 241
Study 27054824 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported alliance
Number of subjects: 241
Study 27054824 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-reported alliance
Number of subjects: 241
Study 27054824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled level of alliance from both partners
Number of subjects: 241
Study 24491134 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement as Medicine for Type 2 Diabetes intervention
Number of subjects: 0
Study 24491134 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 0
Study 22407494 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 52
Study 22407494 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 52
Study 20039105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole slow-release formulations
Number of subjects: 15
Study 20039105 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation
Number of subjects: 15
Study 17681969 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual oxybutynin 5 mg every 8 h during the 24 h after surgery
Number of subjects: 46
Study 17681969 — intervention group
Group type: COMPARATOR
Intervention: placebo every 8 h during the 24 h after surgery
Number of subjects: 46
Study 17681969 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual oxybutynin 5 mg
Number of subjects: 46
Study 17681969 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 16185789 — intervention group
Group type: EXPERIMENTAL
Intervention: Calshake
Number of subjects: 60
Study 16185789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure plus
Number of subjects: 60
Study 16185789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortijuce
Number of subjects: 60
Study 16185789 — intervention group
Group type: COMPARATOR
Intervention: Calshake (Control)
Number of subjects: 60
Study 16185789 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preference after chemotherapy
Number of subjects: 60
Study 11809169 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization transfer (MT) and diffusion tensor (DT) magnetic resonance imaging (MRI) in fatigued patients
Number of subjects: 28
Study 11809169 — intervention group
Group type: COMPARATOR
Intervention: Magnetization transfer (MT) and diffusion tensor (DT) magnetic resonance imaging (MRI) in non-fatigued patients
Number of subjects: 28
Study 11809169 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue severity scale scores in fatigued patients
Number of subjects: 28
Study 11809169 — intervention group
Group type: COMPARATOR
Intervention: Fatigue severity scale scores in non-fatigued patients
Number of subjects: 28
Study 10364025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal isobaric distension (tonic mode)
Number of subjects: 51
Study 10364025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal isobaric distension (phasic mode)
Number of subjects: 51
Study 7734251 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 100
Study 7734251 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 100
Study 2040934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (300 mg for the first month, 400 mg for the second month, 600 mg for the third month)
Number of subjects: 19
Study 2040934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (13.4 +/- 4.1 mg/kg)
Number of subjects: 19
Study 2040934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 19
Study 2040934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7075655 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg and codeine phosphate 60 mg
Number of subjects: 32
Study 7075655 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate 60 mg
Number of subjects: 32
Study 7075655 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 32
Study 7075655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30928823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (4 mg/day)
Number of subjects: 800
Study 30928823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 29986902 — intervention group
Group type: EXPERIMENTAL
Intervention: Bobath plus dry needling
Number of subjects: 26
Study 29986902 — intervention group
Group type: COMPARATOR
Intervention: Bobath only
Number of subjects: 26
Study 27625743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-provided telephonic medication therapy management (MTM)
Number of subjects: 25
Study 27625743 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 25
Study 25046167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 10-100 mg
Number of subjects: 16
Study 25046167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 60-80 mg
Number of subjects: 16
Study 25046167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod 40 mg
Number of subjects: 16
Study 25046167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod
Number of subjects: 16
Study 22933494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidised zirconium (OxZr) femoral component
Number of subjects: 331
Study 22933494 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chromium (CoCr) femoral component
Number of subjects: 331
Study 22933494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OxZr and CoCr femoral components
Number of subjects: 331
Study 20105318 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient group
Number of subjects: 0
Study 20105318 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician group
Number of subjects: 0
Study 17925136 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment combined with supervised exercises
Number of subjects: 102
Study 17925136 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 102
Study 16301359 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 56
Study 16301359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 12085184 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel
Number of subjects: 104
Study 12085184 — intervention group
Group type: COMPARATOR
Intervention: methotrexate and 5‐fluorouracil
Number of subjects: 104
Study 12085184 — intervention group
Group type: EXPERIMENTAL
Intervention: low microvessel density
Number of subjects: 104
Study 9451311 — intervention group
Group type: EXPERIMENTAL
Intervention: port/bag
Number of subjects: 208
Study 9451311 — intervention group
Group type: COMPARATOR
Intervention: cap/bottle
Number of subjects: 208
Study 7889180 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 116
Study 7889180 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 116
Study 7889180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 7889180 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous estrogen/progestogen
Number of subjects: 116
Study 7889180 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 116
Study 7889180 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 116
Study 7889180 — intervention group
Group type: COMPARATOR
Intervention: Nonfractured women (control group)
Number of subjects: 116
Study 2692687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide plus long-acting propranolol (80 mg)
Number of subjects: 23
Study 2692687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide plus long-acting propranolol (160 mg)
Number of subjects: 23
Study 2692687 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide alone
Number of subjects: 23
Study 358658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonazolac
Number of subjects: 2
Study 358658 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 2
Study 358658 — intervention group
Group type: COMPARATOR
Intervention: Oxyphenbutazone
Number of subjects: 2
Study 31044536 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adult DBT programme
Number of subjects: 37
Study 31044536 — intervention group
Group type: COMPARATOR
Intervention: General adult DBT programme
Number of subjects: 37
Study 30606198 — intervention group
Group type: EXPERIMENTAL
Intervention: TREAT format (structured journal club)
Number of subjects: 19
Study 28736322 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 242
Study 28736322 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (high volume disease)
Number of subjects: 242
Study 28736322 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (low volume disease)
Number of subjects: 242
Study 28736322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 25818060 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone plus standard medical management
Number of subjects: 375
Study 25818060 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid agonist therapy
Number of subjects: 375
Study 25818060 — intervention group
Group type: COMPARATOR
Intervention: No agonist therapy
Number of subjects: 375
Study 25818060 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in agonist therapy
Number of subjects: 375
Study 25818060 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up study participants
Number of subjects: 375
Study 25818060 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of heroin use
Number of subjects: 375
Study 23633201 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mixed meal test (MMT)
Number of subjects: 4
Study 23633201 — intervention group
Group type: COMPARATOR
Intervention: Gastrostomy mixed meal test (MMT)
Number of subjects: 4
Study 22029232 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin hydrochloride (test formulation)
Number of subjects: 32
Study 19809225 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-minute phenol application
Number of subjects: 110
Study 19809225 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute phenol application
Number of subjects: 110
Study 19809225 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute phenol application
Number of subjects: 110
Study 16965992 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 60
Study 16965992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15559215 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 0
Study 15559215 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus ASA
Number of subjects: 0
Study 15559215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11837878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipe organs
Number of subjects: 43
Study 11837878 — intervention group
Group type: COMPARATOR
Intervention: Digital organs
Number of subjects: 43
Study 9163933 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced depressive mood state
Number of subjects: 0
Study 9163933 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7960211 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (3 months)
Number of subjects: 57
Study 7960211 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin (9 months)
Number of subjects: 57
Study 7960211 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene (9 months)
Number of subjects: 57
Study 2897517 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune serum globulin (ISG) given intramuscularly before and 1 week after transfusion
Number of subjects: 291
Study 2897517 — intervention group
Group type: COMPARATOR
Intervention: No additional protection (Control)
Number of subjects: 291
Study 29229430 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive Self-Management Program for Effects of Cancer Treatment (PROSPECT), 8 weeks duration
Number of subjects: 60
Study 29229430 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 27297426 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with extra-virgin olive oil (EVOO)
Number of subjects: 2453
Study 27297426 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet supplemented with tree nuts
Number of subjects: 2453
Study 27297426 — intervention group
Group type: COMPARATOR
Intervention: MedDiet + EVOO
Number of subjects: 2453
Study 25704601 — intervention group
Group type: COMPARATOR
Intervention: pantoprazole for 45 days
Number of subjects: 14
Study 22728166 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (vitamins E 1200 IU and C 1000 mg)
Number of subjects: 59
Study 22728166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 20698249 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30mg/day) plus polaprezinc (150mg/day)
Number of subjects: 163
Study 20698249 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30mg/day)
Number of subjects: 163
Study 18390985 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-ICD
Number of subjects: 334
Study 18390985 — intervention group
Group type: COMPARATOR
Intervention: SC-ICD
Number of subjects: 334
Study 18390985 — intervention group
Group type: COMPARATOR
Intervention: SC-simulated
Number of subjects: 334
Study 16908620 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (400 U/kg 3 times per week)
Number of subjects: 16
Study 16908620 — intervention group
Group type: COMPARATOR
Intervention: Placebo/control
Number of subjects: 16
Study 16908620 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin concentrations > or = 500 mU/mL
Number of subjects: 16
Study 16908620 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin concentrations < 500 mU/mL
Number of subjects: 16
Study 15645891 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Whitestrips Supreme (14% hydrogen peroxide, 100 mg on maxillary strip), used twice daily for 30 minutes for 6 weeks
Number of subjects: 39
Study 15645891 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Whitestrips Supreme (14% hydrogen peroxide, 100 mg on maxillary strip), used twice daily for 30 minutes for 3 weeks
Number of subjects: 39
Study 15645891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11440089 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS)
Number of subjects: 0
Study 11440089 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS)
Number of subjects: 0
Study 9354312 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg orally)
Number of subjects: 10
Study 9354312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8438847 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg in the morning for 2 weeks, followed by 20 mg for an additional 4 weeks if unhealed.
Number of subjects: 241
Study 8438847 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg at night for 2 weeks, followed by open treatment with omeprazole if unhealed.
Number of subjects: 241
Study 8438847 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg treatment.
Number of subjects: 241
Study 3320390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (UK) therapy
Number of subjects: 210
Study 3320390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 30905643 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0 mg faricimab
Number of subjects: 229
Study 30905643 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg faricimab
Number of subjects: 229
Study 30905643 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg ranibizumab
Number of subjects: 229
Study 30905643 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab (both doses)
Number of subjects: 229
Study 29357330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus triamcinolone (TA)
Number of subjects: 48
Study 29357330 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 48
Study 27178725 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-DCT
Number of subjects: 153
Study 27178725 — intervention group
Group type: COMPARATOR
Intervention: DCT
Number of subjects: 153
Study 24630387 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided LV lead placement
Number of subjects: 183
Study 24630387 — intervention group
Group type: COMPARATOR
Intervention: Routine strategy
Number of subjects: 183
Study 22621656 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA and DNase
Number of subjects: 145
Study 22621656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 22621656 — intervention group
Group type: EXPERIMENTAL
Intervention: DNase
Number of subjects: 145
Study 22621656 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 145
Study 20660037 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg iv) alone and in combination with breakfast (550 kcal)
Number of subjects: 16
Study 20660037 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal intake (550 kcal)
Number of subjects: 16
Study 20660037 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (1 mg iv) in combination with breakfast (550 kcal)
Number of subjects: 16
Study 20660037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline) alone and in combination with breakfast
Number of subjects: 16
Study 18815247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tool A training with error-clamp trials
Number of subjects: 0
Study 18815247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tool B exposure after tool A training
Number of subjects: 0
Study 18815247 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-clamp trials after A+B training
Number of subjects: 0
Study 18815247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking memory of tool B over time
Number of subjects: 0
Study 16312918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90
Study 16312918 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what treatment)
Number of subjects: 90
Study 12190903 — intervention group
Group type: EXPERIMENTAL
Intervention: Labial infiltration of 1.0 mL
Number of subjects: 12
Study 12190903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual infiltration of 1.0 mL
Number of subjects: 12
Study 12190903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined labial and lingual infiltration (0.5 mL each)
Number of subjects: 12
Study 12190903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentary injection (118 mL, 2% lidocaine with 1:80,000 adrenaline)
Number of subjects: 12
Study 12190903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentary injection
Number of subjects: 12
Study 12190903 — intervention group
Group type: COMPARATOR
Intervention: Buccal infiltrations
Number of subjects: 12
Study 12190903 — intervention group
Group type: COMPARATOR
Intervention: Lingual infiltrations
Number of subjects: 12
Study 12190903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraligamentary injections
Number of subjects: 12
Study 9706923 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 12 mg i.m. 30 min before surgery (Group B)
Number of subjects: 78
Study 9706923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) (Group P)
Number of subjects: 78
Study 7843443 — intervention group
Group type: EXPERIMENTAL
Intervention: Short GnRH agonist protocol (900 micrograms/d buserelin acetate intranasally from day 1, followed by hMG from day 3)
Number of subjects: 80
Study 7843443 — intervention group
Group type: COMPARATOR
Intervention: hMG administration from day 3 of the menstrual cycle (control group)
Number of subjects: 80